Dapagliflozin Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Dapagliflozin Supply and Availability in 2026

Dapagliflozin (Farxiga) has become a cornerstone therapy across multiple specialties — endocrinology, cardiology, nephrology, and primary care. With expanded FDA indications for heart failure and chronic kidney disease, prescribing volumes have surged. This provider-focused update covers the current supply landscape, prescribing considerations, and tools to help your patients maintain access to this essential medication.

Timeline: Dapagliflozin's Expanding Role

Understanding the regulatory timeline helps contextualize current demand:

• January 2014: FDA approves Dapagliflozin (as Farxiga) for type 2 diabetes mellitus
• May 2020: FDA approves Dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
• May 2020: FDA approves Dapagliflozin for heart failure with reduced ejection fraction (HFrEF), NYHA class II-IV — the first SGLT2 inhibitor to receive this indication regardless of diabetes status
• April 2021: FDA approves Dapagliflozin for chronic kidney disease (CKD) to reduce risk of eGFR decline, ESKD, cardiovascular death, and hospitalization for heart failure
• 2025: Generic Dapagliflozin enters the U.S. market from multiple manufacturers

Each approval expanded the prescriber base and patient population, compounding demand on a supply chain originally designed for a single-indication product.

Prescribing Implications

The multi-indication nature of Dapagliflozin creates several considerations for prescribers:

Dosing Across Indications

• Type 2 diabetes: Start at 5 mg once daily; may increase to 10 mg for additional glycemic control. Requires eGFR ≥45 mL/min/1.73m² for glycemic benefit.
• Heart failure: 10 mg once daily. No eGFR threshold required for initiation (though benefit may attenuate at very low eGFR).
• Chronic kidney disease: 10 mg once daily. Can be initiated at eGFR ≥25 mL/min/1.73m².

Key Monitoring Points

• Monitor eGFR before initiation and periodically thereafter
• Assess volume status, particularly in patients on concurrent diuretic therapy
• Monitor for signs of diabetic ketoacidosis, even in patients with normal glucose levels (euglycemic DKA)
• Screen for genital mycotic infections, particularly in patients with a history of recurrent infections
• Discontinue 3–4 days before planned surgical procedures to mitigate DKA risk

For detailed interaction guidance, refer patients to our resource on Dapagliflozin drug interactions.

Current Availability Picture

As of early 2026, the FDA has not declared a formal shortage of Dapagliflozin. However, intermittent pharmacy-level stock-outs persist, driven by:

• Demand growth: Multi-specialty prescribing has significantly expanded the patient pool
• Generic ramp-up: While generic Dapagliflozin launched in 2025, not all manufacturers have reached full production capacity
• Formulary variability: Payer coverage differs across plans, driving patients between pharmacies and formulations
• Wholesaler allocation: Pharmacy chains may receive limited allocations based on prior ordering history

Independent pharmacies and specialty pharmacies often maintain more flexible supply chains and may serve as better alternatives for patients experiencing stock-outs at chain pharmacies.

Cost and Access Considerations

Cost remains a significant barrier for many patients:

• Brand-name Farxiga: $550–$650/month without insurance
• Generic Dapagliflozin: $288–$405/month with discount coupons (GoodRx, SingleCare)
• AstraZeneca Savings Card: Eligible commercially insured patients may pay as low as $0/fill (max savings $175/fill). Not available for government-insured patients.
• AZ&Me Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients
• Medicare Part D: Coverage varies by plan; patients may benefit from the Inflation Reduction Act's $2,000 annual out-of-pocket cap

When discussing cost with patients, consider directing them to savings resources for Dapagliflozin or to the provider's guide to helping patients save.

Tools and Resources for Your Practice

Several tools can help you and your care team support patients navigating Dapagliflozin access:

• Medfinder for Providers: medfinder.com/providers offers real-time pharmacy availability data that can be shared with patients at the point of prescribing
• Prior Authorization Support: When payers require PA, having documented indication (heart failure, CKD, or diabetes) with relevant clinical markers (eGFR, LVEF, NYHA class) streamlines approval
• Electronic Prescribing: When sending prescriptions electronically, include a note that generic Dapagliflozin is acceptable (unless brand is medically necessary), increasing the likelihood that the pharmacy can fill from available stock
• Patient Education: Direct patients to resources about side effects, finding the medication in stock, and alternatives they can discuss with your team

Looking Ahead

The SGLT2 inhibitor landscape is expected to continue evolving:

• Additional generic manufacturers entering the Dapagliflozin market should further stabilize supply and reduce costs through 2026 and 2027
• Ongoing research into additional indications (e.g., NAFLD/NASH, obesity-related outcomes) could further expand the patient population
• Biosimilar and combination products (like Xigduo XR) provide alternative pathways when standalone Dapagliflozin is unavailable
• Payer landscape: The Inflation Reduction Act's Medicare drug price negotiation program may eventually include SGLT2 inhibitors, potentially affecting pricing and access

Final Thoughts

Dapagliflozin remains one of the most important medications in modern cardiometabolic and renal medicine. While supply is not in formal shortage, providers should be prepared for intermittent availability challenges and have strategies ready to help patients maintain continuity of care.

Bookmark Medfinder for Providers for real-time availability data, and encourage your patients to use Medfinder when they encounter pharmacy stock-outs. For additional provider resources, see our guide on how to help your patients find Dapagliflozin in stock.